Mankind Pharma, India’s fourth-largest pharmaceutical company, has announced a collaboration with OpenAI, a leading AI research and deployment company, to institutionalise AI across its value chain.

The company aims to fully integrate advanced AI into core operations to accelerate innovation and improve operational efficiency. It will integrate OpenAI Enterprise across multiple functions, including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs. The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem, the company said in a statement.

“At Mankind Pharma, we see working with OpenAI as a pivotal step in building the pharma organisation of the future. By integrating advanced AI into our core operations, we’re enabling our teams to move faster, work smarter, and unlock insights that drive real-world impact - whether it’s in field force effectiveness, supply chain agility, or R&D acceleration,” said Arjun Juneja, chief operating officer, Mankind Pharma, in a statement.

According to Juneja, the collaboration with OpenAI is not just about automation; it’s about creating a more responsive, intelligent, and future-ready enterprise. “We’re excited to lead this shift in Indian pharma and set new benchmarks for how technology can drive both operational excellence and long-term value creation.” 

Mankind Pharma’s integration of OpenAI capabilities will allow smarter decision-making through GPT-powered dashboards, providing real-time, data-driven insights across R&D, supply chain, and commercial operations. It will feature automated, multilingual content, offering faster complaint communication for healthcare professionals and patients, ensuring speed, accuracy, and regulatory compliance.

Similarly, function-specific AI agents will help sales and marketing, R&D, and HR to improve efficiency and growth. Streamlining literature reviews and real-time insights from clinical and genomic data, using advanced clinical intelligence, to propel scientific discovery forward, using AI to analyse batch records and sensor data, detecting anomalies early and recommending corrective actions—with unmatched accuracy to redefine manufacturing excellence—are the objectives of this collaboration.

Since July 2025, Mankind Pharma has deployed a wide range of customised GPTs across its workforce, notably enhancing the effectiveness of sales and marketing teams.  

According to Oliver Jay, Managing Director, International at OpenAI, Mankind Pharma’s company-wide adoption of ChatGPT Enterprise demonstrates the practical role AI can play in regulated industries, such as pharmaceuticals. By integrating advanced AI into areas like research, operations, and medical communications, Mankind is taking meaningful steps to improve efficiency and support innovation.

“We look forward to working with them in exploring how AI can be applied responsibly and safely to deliver value within their organisation and across the healthcare ecosystem,” Jay added.